Affordable Access

Publisher Website

Adjuvant Therapy for Colon Cancer

Authors
Journal
Surgical Oncology Clinics of North America
1055-3207
Publisher
Elsevier
Publication Date
Volume
19
Issue
4
Identifiers
DOI: 10.1016/j.soc.2010.07.005
Keywords
  • Adjuvant Therapy
  • Colorectal Cancer
  • Disease-Free Survival
  • 5-Fluorouracilu
Disciplines
  • Medicine

Abstract

Patients are not at risk of dying from a tumor that has been removed; they are at risk of dying from residual microscopic disease not removed at the time of operation. Thus, the goal of an adjuvant treatment, be it chemotherapy, radiation therapy, immunotherapy, or dietary and lifestyle manipulations, is to eradicate any residual, albeit microscopic, metastatic disease that might remain. Stage I disease carries an excellent prognosis, and at present there are no compelling data to support adjuvant chemotherapy for patients with this early stage. Stage II colon cancer also has a good prognosis after operation alone and represents the most complicated and contentious area in decisions regarding the use of adjuvant chemotherapy. Stage III colorectal cancer (TanyN 1–2M 0) represents a group at a higher risk of recurrence, and this population is routinely given adjuvant chemotherapy in the absence of a medical or psychiatric contraindication.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Adjuvant therapy for colon cancer.

on Current gastroenterology repor... October 2007

[Adjuvant therapy for colon cancer].

on Schweizerische medizinische Wo... Nov 18, 2000
More articles like this..